EGFR and cancer: Among the anti-EGFR monoclonal antibodies (cetuximab, panitumumab, nimotuzumab, and necitumumab) used in cancer treatment, cetuximab and panitumumab have been approved for the treatment of metastatic CRC (mCRC).